James Hammond looks at the emergence of portable genetic testing technologies. The solution for safer and more efficient operations onboard
While voluntary vaccinations have played a key role in reducing the risk of hospitalisations and fatalities from Covid-19, they are not a silver bullet. Vaccination does not work well for everyone, and there is a growing body of evidence that they are not preventing infection and are becoming less effective against the more transmissible variants, such as Delta.
Studies from the CDC in the US found that vaccinated people infected with the Delta variant carried tremendous amounts of the virus in the nose and throat. Front line reports from hospitals in Israel, one of the world’s most vaccinated countries showed that 90% of severe covid patients were fully vaccinated. Closer to home you may have seen the recent report from Carnival Cruise Line that their vessel Vista had 26 crew test positive despite them all being vaccinated and not showing any symptoms.
Our consultant clinical scientist and virologist have been advising that ships are higher risk environments for SARS-CoV-2 and moving forward the challenge is how do we minimise the risk of transmission onboard without causing adverse disruption to vessel operations?
How does this technology help?
Imagine a world where you no longer needed to leave the vessel to get tested for Covid-19. Bringing your molecular testing programme in-house gives more control and flexibility to test when and wherever you are. Protecting the crew and guests while maintaining operational efficiency, negating shoreside crew isolation and testing for international travel.